Inhibiting NOX enzymes to treat multiple diseases with high medical need
Posted 13th May 2019 by Joshua Sewell
NOX enzymes are a family of enzymes which amplify multiple signalling pathways associated with liver disease. At the Global NASH Congress, Alexandre Grassin shared a presentation about Genkyotex’s novel molecule GTK831, a NOX1/4 inhibitor, and the interim results from its phase two trial.
NOX stands for a group of enzymes called NADPH Oxidases that amplify multiple signalling pathways. Genkyotex focusses on fibrotic diseases by targeting NOX1 and NOX4 with GKT831, which downregulates the activation of multiple clinically validated fibrogenic and apoptotic pathways.
In this presentation, Alexandre shares the results of the phase 2 trial of GKT831 in patients with Primary Biliary Cholangitis. Interim efficacy analysis was conducted when 92 individuals completed week 6 of the trial. Data demonstrating the primary interim efficacy endpoint of a change in GGT – a marker of liver and bile duct injury – at week 6 compared to the baseline.
The progressive reductions from baseline to week 2 and to week 6 suggest that further improvements can be achieved with continued treatment. Furthermore, the greater GGT reductions in patients with a higher baseline GGT suggest that GKT831 may also benefit patients with more advanced disease.
To find out more about further trial endpoints and data regarding changes in other biomarkers, watch the presentation at your leisure via the links below.
GKT831: A novel PII anti-fibrotic small molecule
 |
Alexandre Grassin talks about GKT831, a novel NOX1/4 inhibitor. GKT831 is evaluated in phase 2 clinical trials in primary biliary cholangitis (PBC) and in an investigator-initiated Phase 2 clinical trial in Type 1 Diabetes and Kidney Disease (DKD). |
More presentations and reports are available for free on the NASH resources page. To see what is available, take a look here.
Leave a Reply
